Table 1.
Study Demographics and Clinical Characteristics (n = 33)
| Mean ± SD | |
|---|---|
| Age, year | 15.3 ± 1.49 |
| BMI z-score | 0.81 ± 0.86 |
| BMI percentile | 73.9 ± 22.1 |
| Naltrexone duration, days | 129 ± 125 |
| Race | n (%) |
| White | 24 (73) |
| Black | 2 (6.1) |
| Hispanic | 5 (15) |
| Asian | 1 (3.0) |
| Other | 1 (3.0) |
| Gender | |
| Female | 29 (88) |
| Male | 1 (3.0) |
| Male to female | 2 (6.1) |
| Female to male | 1 (3.0) |
| Eating disorder diagnosis | |
| Anorexia nervosa-binge/purge subtype | 12 (36) |
| Bulimia nervosa | 12 (36) |
| EDNOS/OSFED | 8 (24) |
| Other | 1 (3) |
| Comorbid diagnoses | |
| Generalized anxiety disorder | 18 (55) |
| Attentive-deficit/hyperactivity disorder | 4 (12) |
| Bipolar disorder | 2 (6.1) |
| Major depressive disorder | 19 (56) |
| Gender dysphoria | 3 (9.1) |
| Nonsuicidal self-injury disorder | 6 (18) |
| Obsessive compulsive disorder | 1 (3.0) |
| Posttraumatic stress disorder (PTSD) | 3 (9.1) |
| Substance use disorder | 3 (9.1) |
| Concomitant medication use | |
| SSRI | 27 (82) |
| Sertraline | 9 (27) |
| Fluoxetine | 15 (45) |
| Escitalopram/citalopram | 4 (12) |
| Other psychotropics | 10 (30) |
| Aripiprazole | 3 (9.1) |
| Dex-/methylphenidate | 2 (6) |
| Lisdexamfetamine | 1 (3.0) |
| Quetiapine | 2 (6) |
| Olanzepine | 2 (6) |
| Guanfacine | 1 (3.0) |
| Prazosin | 1 (3.0) |
| Lamotrigine | 1 (3.0) |
| Hormonal contraceptives | 7 (21) |
| Combined oral contraceptive pills | 5 (15) |
| Medroxyprogesterone | 1 (3.0) |
| Cross-gender hormones (leuprolide, estrogen, and progestin) | 1 (3.0) |
SD, standard deviation; SSRI, selective serotonin reuptake inhibitor; EDNOS/OSFED, eating disorder not otherwise specified, other specified feeding and eating disorders; BMI, body mass index.